This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The authors have made a quantitative analysis of the shape and distribution of focal T2 white matter lesions by means of lesion probability maps and voxel-wise analysis to distinguish neuromyelitis optica spectrum disorders (NMOSD) from multiple sclerosis (MS). Forty-four patients with aquaporin-4 (AQP4) antibody-positive NMOSD and 50 patients with relapsing-remitting MS (RRMS) were enrolled, though 3 of the patients with NMOSD with apparent ischemic brain lesions were excluded from the analyses. Sixty-three percent of patients with NMOSD and all the patients with RRMS had brain lesions, with 27% of the patients with NMOSD fulfilling Barkhof criteria for dissemination in space. The authors found that the criteria of at least one T2 lesion in both the inferior temporal lobe white matter and adjacent to the body of the lateral ventricle or either a juxtacortical lesion with U-fiber type morphology or an ovoid lesion perpendicular to the lateral ventricle (Dawson finger) were able to distinguish RRMS from NMOSD with high accuracy.1
Footnotes
Disclosure: M. Tintore has served on the scientific advisory boards of Teva Pharmaceutical Industries Ltd, Novartis, Sanofi-Aventis, and Genzyme and has received funding for travel and speaker honoraria from Bayer Schering Pharma, Merck Serono, Teva Pharmaceutical Industries Ltd, Novartis, Biogen-Idec, Sanofi-Aventis, and Genzyme. A. Rovira is on the advisory boards of NeuroTEC and Bayer-Schering Pharma. He serves as a consultant for Novartis. He has received speaker honoraria from Bayer Schering Pharma, Sanofi-Aventis, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, and Biogen Idec. He receives research support from Bayer Schering Pharma and has research agreements with Siemens AG. Go to Neurology.org for full disclosures.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard